Indian Court Dismisses "Misconceived" PIL On Rotavirus Vaccine
This article was originally published in Scrip
Executive Summary
An Indian court has dismissed a petition seeking complete trial data pertaining to an indigenous oral rotavirus vaccine (Rotavac) developed through a unique public-private partnership, noting that it is "misconceived" and "motivated with private interest".
You may also be interested in...
Spotlight Back On Indian Rotavirus Vaccine Controversy
A public interest litigation (PIL) has sought to revive efforts to access segregated trial data from an indigenous oral rotavirus vaccine (Rotavac) in India amid concerns that it might be associated with a higher risk of intussusception in certain pockets of the country. And in a further dimension, an expert panel recently brought up a "representation" on the inclusion of intussusception in the vaccine's package insert.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.